Eli Lilly and Co
NYSE:LLY
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
449.16
950.46
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. [ Read More ]
The intrinsic value of one LLY stock under the Base Case scenario is 354.19 USD. Compared to the current market price of 804.62 USD, Eli Lilly and Co is Overvalued by 56%.
Valuation Backtest
Eli Lilly and Co
Run backtest to discover the historical profit from buying and selling LLY stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Eli Lilly Reports Strong Q1 Growth Driven by New Products
Earnings Call Summary
Eli Lilly's first quarter revenue increased by 26%, primarily due to the success of new products Mounjaro and Zepbound. Earnings per share rose by 59% to $2.58. The company saw significant growth in both the U.S. and international markets. Revenue in Europe and the rest of the world increased significantly, driven by strong demand and the approval of new delivery devices for Mounjaro. Despite some supply constraints, the company is optimistic about ramping up production in the second half of 2024. Eli Lilly also raised its full-year revenue guidance to $42.4 billion to $43.6 billion, reflecting its strong performance and growth prospects .
Balance Sheet Decomposition
Eli Lilly and Co
Current Assets | 25.2B |
Cash & Short-Term Investments | 2.6B |
Receivables | 10B |
Other Current Assets | 12.6B |
Non-Current Assets | 38.8B |
Long-Term Investments | 3.1B |
PP&E | 13.6B |
Intangibles | 11.7B |
Other Non-Current Assets | 10.3B |
Current Liabilities | 18.6B |
Accounts Payable | 2.5B |
Accrued Liabilities | 10.3B |
Other Current Liabilities | 5.9B |
Non-Current Liabilities | 32.5B |
Long-Term Debt | 24.6B |
Other Non-Current Liabilities | 8B |
Earnings Waterfall
Eli Lilly and Co
Revenue
|
35.9B
USD
|
Cost of Revenue
|
-7.1B
USD
|
Gross Profit
|
28.8B
USD
|
Operating Expenses
|
-17.5B
USD
|
Operating Income
|
11.3B
USD
|
Other Expenses
|
-5.2B
USD
|
Net Income
|
6.1B
USD
|
Free Cash Flow Analysis
Eli Lilly and Co
USD | |
Free Cash Flow | USD |
LLY Profitability Score
Profitability Due Diligence
Eli Lilly and Co's profitability score is 72/100. The higher the profitability score, the more profitable the company is.
Score
Eli Lilly and Co's profitability score is 72/100. The higher the profitability score, the more profitable the company is.
LLY Solvency Score
Solvency Due Diligence
Eli Lilly and Co's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Eli Lilly and Co's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LLY Price Targets Summary
Eli Lilly and Co
According to Wall Street analysts, the average 1-year price target for LLY is 936 USD with a low forecast of 606 USD and a high forecast of 1 155 USD.
Ownership
LLY Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Price Appreciation
LLY Price
Eli Lilly and Co
Average Annual Return | 38.37% |
Standard Deviation of Annual Returns | 19.64% |
Max Drawdown | -15% |
Market Capitalization | 766.7B USD |
Shares Outstanding | 900 404 992 |
Percentage of Shares Shorted | 0.75% |
LLY News
Last Important Events
Eli Lilly and Co
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Eli Lilly and Co
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 35,000 full-time employees. The firm is engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products across the world. The firm's diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta and Trulicity. Its oncology products include Alimta, Cyramza, Erbitux, Retevmo, Tyvyt and Verzenio. The firm's immunology products consist of Olumiant and Taltz. Its neuroscience products include Cymbalta, Emgality, Reyvow and Zyprexa. Its other therapies consist of Bamlanivimab, etesevimab, Cialis and Forteo. The firm manufactures and distributes its products through facilities in the United States, including Puerto Rico, and about eight other countries. Its products are sold in approximately 120 countries. Its subsidiaries include Acanthas Pharma, Inc., Alnara Pharmaceuticals, Inc., ARMO Biosciences, Inc., and Avid Radiopharmaceuticals, Inc., among others.
Contact
IPO
Employees
Officers
The intrinsic value of one LLY stock under the Base Case scenario is 354.19 USD.
Compared to the current market price of 804.62 USD, Eli Lilly and Co is Overvalued by 56%.